Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

SHANI FRANCIS

Allopathic & Osteopathic Physicians Dermatology

NPI
1043472970
CMS profile
138530
Location
CAMARILLO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$957.72

33 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $957.72 33

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
UCB, Inc. $262.80 7
Lilly USA, LLC $197.96 6
GENZYME CORPORATION $110.19 3
Amgen Inc. $82.83 3
Novartis Pharmaceuticals Corporation $77.40 3
Janssen Biotech, Inc. $65.31 3
ABBVIE INC. $62.58 3
Galderma Laboratories, L.P. $54.44 3
SUN PHARMACEUTICAL INDUSTRIES INC. $27.57 1
Botanix SB Inc $16.64 1

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

SHANI FRANCIS

NPI 1043472970 · CMS profile ID 138530

Allopathic & Osteopathic Physicians / Dermatology

CAMARILLO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043472970?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
SHANI FRANCIS, NPI 1043472970, CMS profile ID 138530. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043472970?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). SHANI FRANCIS, NPI 1043472970, CMS profile ID 138530. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043472970?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
SHANI FRANCIS, NPI 1043472970, CMS profile ID 138530, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1043472970?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

33 matching records · $957.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 33 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–33 of 33.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
UCB, Inc. $5.5211/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224500860 CMS
UCB, Inc. $93.1411/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224500858 CMS
Lilly USA, LLC $18.0407/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186927966 CMS
Lilly USA, LLC $19.6606/25/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186855735 CMS
Amgen Inc. $28.9806/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228323021 CMS
Amgen Inc. $26.6506/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228323025 CMS
Novartis Pharmaceuticals Corporation $25.7106/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200220973 CMS
Galderma Laboratories, L.P. $19.4406/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234641876 CMS
GENZYME CORPORATION $49.1206/03/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233585510 CMS
Botanix SB Inc $16.6405/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1246258873 CMS
ABBVIE INC. $31.8505/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201876065 CMS
Lilly USA, LLC $121.8705/08/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186927964 CMS
ABBVIE INC. $15.2705/07/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201876063 CMS
Janssen Biotech, Inc. $20.4204/30/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174570029 CMS
Janssen Biotech, Inc. $22.3104/04/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174569965 CMS
Lilly USA, LLC $2.0904/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186864029 CMS
Lilly USA, LLC $30.2204/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186878505 CMS
UCB, Inc. $49.1304/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224500856 CMS
UCB, Inc. $3.4103/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224500852 CMS
UCB, Inc. $45.1103/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224500854 CMS
Galderma Laboratories, L.P. $15.0002/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234641874 CMS
Novartis Pharmaceuticals Corporation $22.9302/27/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200220971 CMS
UCB, Inc. $39.2002/20/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224500850 CMS
SUN PHARMACEUTICAL INDUSTRIES INC. $27.5702/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251058149 CMS
GENZYME CORPORATION $43.9002/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233585469 CMS
Novartis Pharmaceuticals Corporation $28.7602/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1200220969 CMS
Amgen Inc. $27.2002/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1228323023 CMS
GENZYME CORPORATION $17.1702/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1233585463 CMS
ABBVIE INC. $15.4601/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1201876061 CMS
Galderma Laboratories, L.P. $20.0001/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1234641872 CMS
UCB, Inc. $27.2901/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1224500848 CMS
Janssen Biotech, Inc. $22.5801/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1174569805 CMS
Lilly USA, LLC $6.0801/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186940195 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,660.67 8
PY2020 $80.67 3
PY2021 $223.93 10
PY2022 $985.65 39
PY2023 $596.21 20
PY2024 $1,679.49 55
PY2025 $957.72 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2022 Principal investigator $1,497.00 1
PY2020 Principal investigator $6,805.00 1
PY2019 Principal investigator $26,523.89 21

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

21 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Incyte Corporation $34.25 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841089
Principal investigator 1 Incyte Corporation $55.42 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841095
Principal investigator 1 Incyte Corporation $69.83 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841103
Principal investigator 1 Incyte Corporation $99.86 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841113
Principal investigator 1 Incyte Corporation $113.02 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841115
Principal investigator 1 Incyte Corporation $148.72 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841121
Principal investigator 1 Incyte Corporation $169.06 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841127
Principal investigator 1 Incyte Corporation $475.35 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841133
Principal investigator 1 Incyte Corporation $839.84 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841141
Principal investigator 1 Incyte Corporation $34.25 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841149
Principal investigator 1 Incyte Corporation $55.42 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841153
Principal investigator 1 Incyte Corporation $69.83 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841157
Principal investigator 1 Incyte Corporation $113.02 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841161
Principal investigator 1 Incyte Corporation $148.72 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841165
Principal investigator 1 Incyte Corporation $169.06 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841169
Principal investigator 1 Incyte Corporation $475.35 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841171
Principal investigator 1 Incyte Corporation $839.84 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841175
Principal investigator 1 Incyte Corporation $57.96 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841177
Principal investigator 1 Incyte Corporation $180.09 10/03/2019 Non-covered Recipient Entity
ASHIRA DERMATOLOGY LLC
Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2) A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream Followed by an Extension Period in Participants With Vitiligo No dispute reported 06/30/2026 743841181
Principal investigator 1 AbbVie, Inc. $1,875.00 07/02/2019 Non-covered Recipient Entity
Ashira Dermatology
M18-891 No dispute reported 06/30/2026 647623819
Principal investigator 1 AbbVie, Inc. $20,500.00 04/23/2019 Non-covered Recipient Entity
Ashira Dermatology
M18-891 No dispute reported 06/30/2026 647623817